Evidence map›Paper›PMID 40958858›Full record

ReviewFrontiers in oncology2025

Boron neutron capture therapy for melanoma: recent advances and future prospects.

Yuanyang Sun, Yun Wang, Shukun Mu, Xiaofeng Wu, Suchun Yu, Zhongming Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuanyang SunSchool of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai, China.
Yun WangDepartment of Radiation Oncology, Shidong Hospital, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
Shukun MuDepartment of Radiation Oncology, Shidong Hospital, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
Xiaofeng WuDepartment of Radiation Oncology, Shidong Hospital, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
Suchun YuDepartment of Pharmacy, Shidong Hospital, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.
Zhongming WangDepartment of Radiation Oncology, Shidong Hospital, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Boron neutron capture therapy (BNCT) is a unique radiotherapy modality that targets and destroys selectively tumor cells that have absorbed boron, while leaving surrounding healthy cells unharmed. Over the course of the last nearly 40 years, several clinical studies of BNCT for melanoma have been conducted in many countries. The results of clinical studies are encouraging, suggesting that BNCT may be a potentially effective method for treating melanoma. In this work, we review the outcomes of clinical study of BNCT for melanoma. Moreover, we provide a concise overview of advancements in accelerator-based neutron source and boron delivery agent (BDA) applied to BNCT for melanoma. Finally, we discuss the areas for further research focus regarding BNCT for melanoma.

Indexed as

accelerator-based neutron sourceboron delivery agentboron neutron capture therapyclinical outcomemelanoma

Identifiers

PMID40958858
PMCPMC12434051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.